(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.38%) $966.30
(-0.36%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 6.60%
Live Chart Being Loaded With Signals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug...
Stats | |
---|---|
本日の出来高 | 26 194.00 |
平均出来高 | 45 775.00 |
時価総額 | 215.00M |
EPS | $0.400 ( 2024-03-15 ) |
次の収益日 | ( $0.193 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 8.14 |
ATR14 | $0.0460 (0.51%) |
Cipher Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
ATD.TO | 0.901 |
RQL.TO | 0.886 |
CCO.TO | 0.87 |
BDT.TO | 0.865 |
PKI.TO | 0.863 |
BDI.TO | 0.863 |
RQN.TO | 0.857 |
CMG.TO | 0.857 |
SNC.TO | 0.837 |
THNC.TO | 0.832 |
10 最も負の相関 | |
---|---|
HOT-UN.TO | -0.899 |
GEO.TO | -0.858 |
LGO.TO | -0.857 |
WEF.TO | -0.852 |
PLRB.V | -0.852 |
HEXO.TO | -0.838 |
BYL.TO | -0.835 |
CRRX.TO | -0.831 |
FIL.TO | -0.831 |
S.TO | -0.827 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cipher Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $21.16M |
総利益: | $17.09M (80.77 %) |
EPS: | $0.820 |
FY | 2023 |
収益: | $21.16M |
総利益: | $17.09M (80.77 %) |
EPS: | $0.820 |
FY | 2022 |
収益: | $20.68M |
総利益: | $16.68M (80.69 %) |
EPS: | $0.250 |
FY | 2021 |
収益: | $21.94M |
総利益: | $18.26M (83.21 %) |
EPS: | $0.0740 |
Financial Reports:
No articles found.
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。